Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $18.75

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $18.75.

Several equities analysts recently issued reports on ATRA shares. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. RODMAN&RENSHAW raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, December 20th. Canaccord Genuity Group increased their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $25.00 price objective on the stock.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock opened at $15.55 on Tuesday. Atara Biotherapeutics has a 52-week low of $6.50 and a 52-week high of $39.50. The company has a fifty day moving average of $12.47 and a 200-day moving average of $9.89. The stock has a market capitalization of $89.57 million, a price-to-earnings ratio of -0.60 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the company earned ($16.50) earnings per share. On average, equities research analysts forecast that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares in the last quarter. State Street Corp raised its position in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 12,677 shares during the period. FMR LLC boosted its position in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Atara Biotherapeutics in the second quarter worth $79,000. 70.90% of the stock is currently owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.